Andere talen Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Aandelen

GHDN

US10501E2019

Beurs gesloten - Deutsche Boerse AG Andere beurzen 08:16:38 21-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,511 ^EUR	+9,07%		+2,61%	+122,17%

17/04	Brainstorm Cell Therapeutics Inc. kondigt aan dat Stacy Lindborg met ingang van 9 mei 2024 terugtreedt als Co-CEO	CI
17/04	Brainstorm Cell Therapeutics Inc. Kondigt wijzigingen in het management aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

BrainStorm Cell Therapeutics to Present New Biomarker Data Suggesting ALS Patients May Benefit From Longer-Term Treatment with NurOwn	20/05
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update	14/05
Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024	17/04
Brainstorm Cell Therapeutics Inc. Announces Management Changes	17/04
BrainStorm Cell Therapeutics Regains Compliance with NASDAQ Minimum Market Value Rule	11/04
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment for Phase 3b Trial in ALS	10/04
BrainStorm Cell Therapeutics Announces Peer-reviewed Publication of Biomarker Data from NurOwn's® Phase 3 Clinical Trial in ALS	10/04
Brainstorm Cell Therapeutics Says FDA Agrees on Design of Phase 3B ALS Trial	09/04
BrainStorm Cell Therapeutics Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Phase 3b Trial in ALS	09/04
BrainStorm Cell Therapeutics Inc. Announces Agreement with FDA on Special Protocol Assessment for Phase 3b Trial in ALS	09/04
BrainStorm Cell Therapeutics to Provide Update on NurOwn Program	08/04
Brainstorm Cell Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update	01/04
North American Morning Briefing : Stocks Set for -2-	28/03
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn Trial Design at MDA Clinical and Scientific Conference	28/02
BrainStorm Cell Therapeutics to Unveil Phase 3b NurOwn® Trial Design at MDA Clinical and Scientific Conference	27/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	26/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment (SPA) Request to FDA for Phase 3b Trial of NurOwn® in ALS	23/02
BrainStorm Cell Therapeutics Submits Special Protocol Assessment Request to FDA for Phase 3b Trial of NurOwn in ALS	23/02
BrainStorm Cell Therapeutics to Present at European Life Sciences CEO Forum	13/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG

Aandelen

GHDN

US10501E2019

Andere talen

Filters